

Leonid D Zamora

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4411179/publications.pdf>

Version: 2024-02-01

19
papers

436
citations

933264

10
h-index

940416

16
g-index

19
all docs

19
docs citations

19
times ranked

443
citing authors

#	ARTICLE	IF	CITATIONS
1	Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study. Arthritis Care and Research, 2022, 74, 2033-2041.	1.5	6
2	“Not at target”: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. Arthritis Research and Therapy, 2022, 24, 70.	1.6	17
3	Physician Global Assessment International Standardisation CONsensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatology, The, 2022, 4, e441-e449.	2.2	17
4	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. Rheumatology, 2021, 60, 5185-5193.	0.9	9
5	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet Rheumatology, The, 2021, 3, e517-e531.	2.2	26
6	Lupus education for physicians and patients in a resource-limited setting. Clinical Rheumatology, 2020, 39, 697-702.	1.0	5
7	Risk factors for herpes zoster infection among Filipinos with systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2020, 23, 197-202.	0.9	12
8	Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. Lancet Rheumatology, The, 2020, 2, e24-e30.	2.2	45
9	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. International Journal of Rheumatic Diseases, 2020, 23, 1255-1257.	0.9	12
10	Serotonin syndrome masquerading as disease flare in lupus nephritis with end-stage renal disease. International Journal of Rheumatic Diseases, 2019, 22, 1933-1936.	0.9	5
11	Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. Lancet Rheumatology, The, 2019, 1, e103-e110.	2.2	38
12	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatology, The, 2019, 1, e95-e102.	2.2	65
13	OP0246...ATTAINMENT OF THE LUPUS LOW DISEASE ACTIVITY STATE IS ASSOCIATED WITH PROTECTION FROM DAMAGE ACCRUAL IN PATIENTS WITH ACTIVE DISEASE AT BASELINE. , 2019, , .		0
14	OP0330...#X00A0; COMPARISON OF THE EFFECTS OF DORIS REMISSION AND LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) ON DISEASE OUTCOMES IN A MULTINATIONAL PROSPECTIVE STUDY. , 2019, , .		0
15	THU0253...EFFECT OF GLUCOCORTICOIDS ON DAMAGE ACCRUAL IN SLE PATIENTS WITH NO CLINICAL OR SEROLOGICAL DISEASE ACTIVITY. , 2019, , .		0
16	Development of the Asia Pacific Lupus Collaboration cohort. International Journal of Rheumatic Diseases, 2019, 22, 425-433.	0.9	24
17	Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Research and Therapy, 2017, 19, 62.	1.6	100
18	Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Research and Therapy, 2016, 18, 260.	1.6	44

#	ARTICLE	IF	CITATIONS
19	Biologic therapies in systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2015, 18, 146-153.	0.9	11